Iressa
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Skin Cancer
Conditions
Skin Cancer
Trial Timeline
May 1, 2004 → Oct 1, 2012
NCT ID
NCT00054691About Iressa
Iressa is a phase 2 stage product being developed by AstraZeneca for Skin Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00054691. Target conditions include Skin Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00054691 | Phase 2 | Completed |
| NCT00319787 | Phase 2 | Completed |
Competing Products
20 competing products in Skin Cancer